Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?

Dipeptidyl peptidase-4 inhibitors are a relatively new class of oral anti-hyperglycaemic drugs to treat type 2 diabetes through prevention of degradation of incretins by the dipeptidyl peptidase-4 enzyme. The large trials evaluating the dipeptidyl peptidase-4 inhibitors sitagliptin, alogliptin and s...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanssen, Nordin MJ, Jandeleit-Dahm, Karin AM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613297/
https://www.ncbi.nlm.nih.gov/pubmed/31018682
http://dx.doi.org/10.1177/1479164119842339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613297/
https://www.ncbi.nlm.nih.gov/pubmed/31018682
http://dx.doi.org/10.1177/1479164119842339

Ejemplares similares